Back

Estimated multinational budget impact of empagliflozin for heart failure patients with full spectrum of left ventriclular ejection fraction

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Vericiguat, SGLT2 inhibitors and implementation Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Eun-Young Kim

Seoul St. Marys Hospital, Seoul (Korea (Republic of))

6 More presentations in this session

Presentation thumbnail
A placebo-correcetd effect of the initial eGFR decline following SGLT-2 inhibitor initiation: a systematic review and meta-analysis
Doctor S. Urban (Lubin, PL)
Abstract Slides Video
Presentation thumbnail
Scarred for life - outcomes of ischaemic and non-ischaemic cardiomyopathy after heart failure optimisation
Doctor O. Graham (Craigavon, GB)
Abstract Slides Video
Presentation thumbnail
Vericiguat in a real-world heart failure population: a single-centre experience
Mr C. Palacios-Castello (Seville, ES)
Abstract Slides Video
Presentation thumbnail
Quantifying the burden of potentially inappropriate prescribed medicines among people hospitalised with heart failure in Australia: a comparison with ESC recommendations
Associate Professor M. Falster (Sydney, AU)
Abstract Slides Video
Presentation thumbnail
The effect of dapagliflozin on the microvascular endothelial cell function and metabolism in patients with heart failure: a preliminary report
Doctor M. Tarnawska (Gdansk, PL)
Abstract Slides Video

Access the full session

Session thumbnail
Vericiguat, SGLT2 inhibitors and implementation

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Impact of SGLT2 inhibitor on renal function and cardiovascular outcomes in heart failure: Korean heart failure III registry
thumbnail
Congress Presentation
A value-based analysis of the systematic use of dapagliflozin in patients with heart failure
thumbnail
Congress Presentation
Outcomes of empagliflozin versus dapagliflozin treatment in patients with heart failure based on left ventricular ejection fraction: a multicentre cohort study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources